EZH2 作为骨髓瘤诱导的骨质解脱性骨破坏的可行的治疗点
Rui Liu1, Zongwei Li2, Rui Chen1
1Cancer Research Center, School of Medicine, Xiamen University, Xiamen, China.
Nature communications
|January 30, 2025
概括
骨髓瘤细胞激活增强器的zeste同源2 (EZH2),这使EMP1瘤抑制基因沉默,导致骨损伤. EZH2抑制剂有效地治疗这些骨髓瘤诱导的骨并发症.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 骨生物学 骨生物学 骨生物学
背景情况:
- 骨髓瘤性骨病涉及性骨损伤,疼痛和骨折,需要治疗策略.
- 驱动骨髓瘤诱导的骨破坏的分子机制需要进一步阐明.
研究的目的:
- 为了调查增强器的作用,在骨髓瘤相关骨疾病的发病过程中,zeste同源2 (EZH2).
- 确定治疗瘤骨并发症管理的治疗点.
主要方法:
- 研究了由脂肪细胞衍生细胞因子刺激的髓瘤细胞中的EZH2表达.
- 分析了EZH2,AP2α和EMP1基因促进体之间的相互作用.
- 在骨髓瘤骨病的临床前模型中评估EZH2抑制剂的疗效.
主要成果:
- 骨髓瘤相关的脂肪细胞细胞因子激活骨髓瘤细胞中的EZH2表达.
- EZH2与AP2α形成复合体,导致H3K27me3和EMP1瘤抑制基因的沉默.
- 沉默EMP1促进髓瘤细胞增殖和骨解细胞因子分泌,有助于骨破坏.
- 抑制EZH2有效地改善了骨髓瘤诱导的骨折性骨损伤.
结论:
- EZH2通过沉默EMP1瘤抑制剂,在髓瘤诱导的骨疾病中发挥关键作用.
- 用抑制剂向EZH2为骨髓瘤骨病提供了一个有前途的治疗策略.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Antiepileptic Drugs: Potassium Channel Activators
142
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
142
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K


